Neurocrine Biosciences, Inc. announced the presentation of new one-year data from the CAHtalyst Adult study of CRENESSITY, showing that patients achieved lasting, more physiologic glucocorticoid (GC) doses. Adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone, and androstenedione remained at or below baseline levels.
These data, presented at the Endocrine Society's Annual Meeting, ENDO 2025, complement the recently announced CAHtalyst Pediatric one-year results. The Phase 3 CAHtalyst Adult study included 182 adult patients, 18 to 58 years of age, and consisted of a 24-week double-blind, placebo-controlled period followed by a 24-week open-label period.
Mean GC dose was reduced by 25% for the continuous CRENESSITY group and 30% for the placebo to CRENESSITY group at Month 12, with androstenedione maintained or reduced below Day 1 baseline. CRENESSITY demonstrated a consistent safety profile, with most side effects being temporary and mild to moderate in severity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.